Marta Boffito - Stopping/Switching Considerations When Using La-ARVs

Chinese HIV Clinical Forum 2022

Lili Dai - Rapid ART Initiation Using BIC/FTC/TAF and TDF+3TC+EFV in HIV Positive Patients in China: A Randomized Controlled Trial

Chinese HIV Clinical Forum 2022

Rapid ART Initiation Using BIC/FTC/TAF and TDF+3TC+EFV in HIV Positive Patients in China: A Randomized Controlled Trial - Lili Dai, PhD

Chinese HIV Clinical Forum 2022

International Data Supporting Rapid Start - Chien-Ching Hung, MD, PhD

Chinese HIV Clinical Forum 2022

Stopping/Switching Considerations When Using La-ARVs - Marta Boffito, MD, PhD, FRCP

Chinese HIV Clinical Forum 2022

Update on Long Acting Therapeutic Options for HIV Treatment - Jean-Michel Molina, MD, PhD

Chinese HIV Clinical Forum 2022

Switching to Newer (Reduced) Drug Regimens in Patients Suppressed on Older Drugs - Nicholas Paton, MD, FRCP

Chinese HIV Clinical Forum 2022

Pharmacological Considerations in Choice of Regimen - Andrea Calcagno, MD, DTM&H

Chinese HIV Clinical Forum 2022

HIV Low-Level Viremia and New Approach to Drug Resistance Surveillance - Fujie Zhang, MD, PhD

Chinese HIV Clinical Forum 2022

Resistance Considerations in Choice of Regimen - Kiat Ruxrungtham, MD

Chinese HIV Clinical Forum 2022

Short Talk: Cabotegravir/Rilpivirine Failures Despite Adherence - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Short Talk: Islatravir Toxicity - Charles Flexner, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Point of Care Tests for Drug Level Testing: Where Are We? - Paul K. Drain, MD, MPH, FIDSA

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Strategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals - Adeniyi Olagunju, BPharm, MRes, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Multipurpose Prevention Technologies (MPTs) For Prevention of HIV and Pregnancy - Sharon L. Hillier, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacokinetics of mAbs in Prevention, Treatment and Cure of Viral Infections -Edmund Capparelli, PharmD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Optimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals -Angela Colbers, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacology Pearls for Managing Absorption and Swallowing Difficulties - Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Age-Related Changes in Pharmacokinetics and Pharmacodynamics - Catia Marzolini, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

The Non-adherent Patient: A Good or Bad Candidate for CAB+RPV? - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir for Treatment and Prevention - M. Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir for Treatment and Prevention: When Are You Protected? - M. Boffito, MD, PhD, FRCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

What’s on the Horizon for Direct Acting Antivirals for Hepatitis B? - Jennifer Kiser, PharmD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Recent Developments in Antivirals Against Herpes Simplex Virus Infection - Scott H. James, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022